Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Hypopharyngeal Cancer: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Hypopharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hypopharyngeal Cancer

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Soft Tissue Sarcoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Soft Tissue Sarcoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Soft Tissue Sarcoma

Data Insights

Docetaxel albumin bound by CSPC Pharmaceutical Group for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Recurrent Head And...

Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel Albumin Bound in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Docetaxel albumin bound by CSPC Pharmaceutical Group for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Oral Cavity (Mouth)...

Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel Albumin Bound in Oral Cavity (Mouth) Cancer

Data Insights

Docetaxel albumin bound by CSPC Pharmaceutical Group for Oropharyngeal Cancer: Likelihood of Approval

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Oropharyngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel Albumin Bound in Oropharyngeal Cancer

Data Insights

Docetaxel albumin bound by CSPC Pharmaceutical Group for Laryngeal Cancer: Likelihood of Approval

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Laryngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel Albumin Bound in Laryngeal Cancer

Data Insights

Docetaxel albumin bound by CSPC Pharmaceutical Group for Hypopharyngeal Cancer: Likelihood of Approval

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Hypopharyngeal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel Albumin Bound in Hypopharyngeal Cancer

Data Insights

Irinotecan hydrochloride by CSPC Pharmaceutical Group for Ewing Sarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Ewing Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Ewing Sarcoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Hepatocellular Carcinoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hepatocellular Carcinoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Sezary Syndrome: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Sezary Syndrome. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Sezary Syndrome

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Acute Myelocytic Leukemia (AML,...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Relapsed Acute Myeloid Leukemia

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Refractory Acute Myeloid Leukemia

Data Insights

DP-303c by CSPC Pharmaceutical Group for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

DP-303c by CSPC Pharmaceutical Group for Epithelial Ovarian Cancer: Likelihood of Approval

DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Epithelial Ovarian Cancer

Data Insights

DP-303c by CSPC Pharmaceutical Group for Peritoneal Cancer: Likelihood of Approval

DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Peritoneal Cancer

Data Insights

DP-303c by CSPC Pharmaceutical Group for Fallopian Tube Cancer: Likelihood of Approval

DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Fallopian Tube Cancer

Data Insights

DP-303c by CSPC Pharmaceutical Group for Metastatic Breast Cancer: Likelihood of Approval

DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Metastatic Breast Cancer

Data Insights

Narlumosbart by CSPC Pharmaceutical Group for Giant Cell Tumor Of Bone: Likelihood of Approval

Narlumosbart is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Giant Cell Tumor Of Bone....

Likelihood of Approval and Phase Transition Success Rate Model - Narlumosbart in Giant Cell Tumor Of Bone

Data Insights

Narlumosbart by CSPC Pharmaceutical Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval

Narlumosbart is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Humoral Hypercalcemia of Malignancy. According...

Likelihood of Approval and Phase Transition Success Rate Model - Narlumosbart in Humoral Hypercalcemia of Malignancy